EUCTR2005-005887-97-IS进行中（未招募）不适用
Open-label study of bevacizumab (AVASTIN®) in combination with platinum-containing chemotherapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer - SAI
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 2,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients included in the study should have the following criteria:
- •1. Written informed consent (informed consent document to be approved by the institution’s Independent Ethics Committee and patient consent obtained prior to any study-specific procedure)
- •2. Age =18 years
- •3. Able to comply with the protocol
- •4. Histologically or cytologically documented inoperable, locally advanced (Stage IIIb with supraclavicular lymph node metastases or malignant pleural or pericardial effusion), metastatic (Stage IV) or recurrent NSCLC other than squamous cell (tumours of mixed histology should be categorized by the predominant cell type)
- •5. ECOG PS 0-2
- •6. Life expectancy =12 weeks
- •7. Adequate haematological function
- •- Absolute neutrophil count (ANC) =1.5 x 10[9]/L AND
- •- Platelet count =100 x 10[9]/L AND
- •- Haemoglobin =9 g/dL (may be transfused to maintain or exceed this level)
- •8. Adequate liver function
- •- Total bilirubin <1.5 x ULN AND
- •- Asparagine aminotransferase (AST), alanine aminotransferase (ALT) <2.5 x ULN in patients without liver metastases; <5 x ULN in patients with liver metastases
- •9. Adequate renal function
- •- Serum creatinine =1.25 x ULN or calculated creatinine clearance =50 mL/min AND
- •- Urine dipstick for proteinuria <2+. Patients discovered to have =2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate =1 g of protein in 24 hours
- •10. INR =1.5 and PTT =1.5 x ULN within 7 days prior to enrolment
- •11. If female, should not be pregnant or be breast-feeding. Women with an intact uterus (unless amenorrhoeic for the last 24 months) must have a negative serum pregnancy test within 28 days prior to enrolment into the study. If a serum pregnancy test is not performed within 7 days prior to the first dose of bevacizumab, a confirmatory urine test (within 7 days prior to the first dose of bevacizumab) is required.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with any of the following will be excluded from study entry:
- •1. Mixed, non-small cell and small cell tumours or mixed adenosquamous carcinomas with a predominant squamous component
- •2. History of haemoptysis, defined as bright red blood of at least half a teaspoon in the 3 months prior to enrolment
- •3. Evidence of tumour invading major blood vessels on imaging. The investigator or the local radiologist must exclude evidence of tumour that is fully contiguous with, surrounding, or extending into the lumen of a major blood vessel (e.g. pulmonary artery or superior vena cava)
- •4. Evidence of CNS metastases, even if previously treated. If suspected, the patient should be scanned within 28 days prior to enrolment to rule out CNS metastases
- •5. Neoadjuvant/adjuvant chemotherapy within 6 months prior to enrolment
- •6. Radiotherapy within 28 days prior to enrolment
- •7. Major surgery (including open biopsy), significant traumatic injury within 28 days prior to enrolment or anticipation of the need for major surgery during study treatment
- •8. Minor surgery, including insertion of an indwelling catheter, within 24 hours prior to the first bevacizumab infusion
- •9. Current or recent use of aspirin (>325 mg/day)
- •10. Current or recent (within 10 days of first dose of bevacizumab) use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes. Prophylactic use of anticoagulants is allowed
- •11. History of evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding
- •12. Uncontrolled hypertension (systolic >150 mmHg and/or diastolic >100 mmHg)
- •13. Clinically significant (i.e. active) cardiovascular disease for example CVA (=6 months before enrolment), myocardial infarction (=6 months before enrolment), unstable angina, CHF NYHA Class =II, serious cardiac arrhythmia requiring medication during the study and might interfere with regularity of the study treatment, or not controlled by medication
- •14. Non-healing wound, active peptic ulcer or bone fracture
- •15. History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment
- •16. Women with an intact uterus (unless amenorrhoeic for the last 24 months) not using effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile). Men who do not agree to use effective contraception during the study and for a period of 60 days following the last administration of bevacizumab
- •17. Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to enrolment
- •18. Known hypersensitivity to bevacizumab and any of its excipients, and any of the chemotherapies
- •19. Evidence of any other disease, neurological or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications.
研究者
相似试验
进行中（未招募）
不适用
Open-label study of bevacizumab (AVASTIN®) in combination with platinum-containing chemotherapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer - SAIAdvanced or recurrent non-squamous non-small cell lung cancerMedDRA version: 9Level: PTClassification code 10059515EUCTR2005-005887-97-EEF. Hoffmann-La Roche Ltd2,000
进行中（未招募）
不适用
Open-label study of bevacizumab (AVASTIN®) in combination with platinum-containing chemotherapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer - SAIAdvanced or recurrent non-squamous non-small cell lung cancerMedDRA version: 9Level: PTClassification code 10059515EUCTR2005-005887-97-ATF. Hoffmann-La Roche Ltd2,000
进行中（未招募）
不适用
Open-label study of bevacizumab (AVASTIN®) in combination with platinum-containing chemotherapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer - SAIEUCTR2005-005887-97-SEF. Hoffmann-La Roche Ltd2,000
进行中（未招募）
不适用
Open-label study of bevacizumab (AVASTIN®) in combination with platinum-containing chemotherapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer - SAIEUCTR2005-005887-97-HUF. Hoffmann-La Roche Ltd2,000
进行中（未招募）
不适用
Open-label study of bevacizumab (AVASTIN®) in combination with platinum-containing chemotherapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer - SAIAdvanced or recurrent non-squamous non-small cell lung cancerMedDRA version: 9Level: PTClassification code 10059515EUCTR2005-005887-97-DEF. Hoffmann-La Roche Ltd2,000